Resources from the same session
Prevalence of gastroenteropancreatic and lung neuroendocrine tumours in the European Union
Presenter: Aurore Bergamasco
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs)
Presenter: Martin Gutierrez
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
Pediatric, adolescent and young adult (PAYA) thyroid carcinoma harbors frequent and diverse targetable genomic alterations including kinase fusions
Presenter: Pierre Vanden Borre
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
Pancreatic neuroendocrine tumour (pNET) profiles in the NETwork! programme: clinic–enabled genomics for genomic-enabled clinical decisions
Presenter: Ben Lawrence
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
Presentation
NETTER-1 phase III in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate: Efficacy, safety, QoL results and subgroup analysis
Presenter: Jonathan Strosberg
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
Multicentre evaluation of the role of Gallium DOTA-PET (GaPET) imaging in well differentiated bronchial carcinoids (BC): Impact on patients' (pts) management
Presenter: Angela Lamarca
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
Metformin impact on progression-free survival in diabetic patients with advanced pancreatic neuroendocrine tumors (pNET) receiving everolimus and/or somatostatin analogues. The PRIME-NET (Pancreatic multicentric, Retrospective, Italian MEtformin) study
Presenter: Sara Pusceddu
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
Invited discussant abstracts 427PD and 428PD
Presenter: Xavier Matias-Guiu
Session: Endocrine and neuroendocrine tumours
Resources:
Presentation
Webcast
Invited discussant abstracts 416O and 417O
Presenter: James Yao
Session: Endocrine and neuroendocrine tumours
Resources:
Presentation
Webcast
Integrated placebo-controlled safety analysis from clinical studies of telotristat ethyl for the treatment of carcinoid syndrome
Presenter: Matthew Kulke
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.